Inhibitory peptides of viral infection

Patent metadata

Field	Value
Publication number	US-9683017-B2
Application number	US-201514801717-A
Country	US
Kind code	B2
Filing date	Jul 16, 2015
Priority date	Jul 17, 2014
Publication date	Jun 20, 2017
Grant date	Jun 20, 2017

Abstract

Disclosed are methods of treating and/or inhibiting a viral infection in a subject. The methods include administering a therapeutically effective amount of heparin-binding peptide. Also disclosed herein are methods for blocking viral binding to a cell. Further disclosed are anti-viral compositions for administration to a subject infected with a virus. Administration of the anti-viral composition inhibits viral infection of the subject.

First claim

We claim:

1. A method for reducing a viral infection in a subject, comprising: selecting a subject in whom the viral infection is to be reduced; and
administering to the subject an effective amount of a heparin-binding peptide comprising an amino acid sequence at least 95% identical to the amino acid sequence set forth as any one of SEQ ID NOs: 1-10, thereby reducing the viral infection in the subject.

2. The method of claim 1 , wherein the virus is an enveloped DNA virus or enveloped RNA virus.

3. The method of claim 1 , wherein the virus is a herpesvirus.

4. The method of claim 3 , wherein the herpesvirus is HSV-1.

5. The method of claim 3 , wherein the herpesvirus is cytomegalovirus (CMV).

6. The method of claim 1 , wherein the virus is human immunodeficiency virus (HIV).

7. A method for reducing binding of a virus to a cell, comprising: contacting a cell with an effective amount of a heparin-binding peptide, the heparin-binding peptide comprising an amino acid sequence at least 95% identical to the amino acid sequence set forth as any one of SEQ ID NOs: 1-10.

8. The method of claim 7 , wherein the virus is an enveloped DNA virus or enveloped RNA virus.

9. The method of claim 7 , wherein the virus is a herpesvirus.

10. The method of claim 9 , wherein the herpesvirus is HSV-1.

11. The method of claim 10 , wherein the herpesvirus is cytomegalovirus (CMV).

12. The method of claim 7 , wherein the virus is human immunodeficiency virus (HIV).

13. The method of claim 7 , wherein the heparin-binding peptide set forth as any one of SEQ ID NOs: 1-10 is a D-form peptide.

14. The method of claim 13 , wherein the D-form of the heparin-binding peptide comprises an amino acid sequence at least 95% identical to the amino acid sequence set forth as SEQ ID NO: 6.

15. The method of claim 7 , wherein contacting the cell with the effective amount of a heparin-binding peptide reduces viral infection of the cell.

16. An anti-viral composition, the composition comprising: a heparin-binding peptide, the heparin-binding peptide comprising an amino acid sequence at least 95% identical to the amino acid sequence set forth as any one of SEQ ID Nos. 3-10.

17. The anti-viral composition of claim 16 , wherein the heparin-binding peptide is present in an effective amount to reduce viral infection in a subject infected with a virus by at least 60%.

18. The anti-viral composition of claim 16 , wherein the heparin-binding peptide is present in an effective amount to reduce herpesvirus infection in a subject infected with herpesvirus.

19. The anti-viral composition of claim 16 , wherein the heparin-binding peptide is present in an effective amount to reduce cytomegalovirus infection in a subject infected with cytomegalovirus.

20. The anti-viral composition of claim 16 , wherein the heparin-binding peptide is present in an effective amount to reduce human immunodeficiency virus (HIV) infection in a subject infected with HIV.

Assignees

• Univ Tennessee Res Found
• Univ Tennessee Res Found

Inventors

• Wall Jonathan S
• Sparer Timothy E
• Kennel Stephen J

Classifications

• C07K7/08 Primary

  having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) · CPC title

• C07K14/045

  Cytomegalovirus · CPC title

• C07K14/035

  Herpes simplex virus I or II · CPC title

• A61K38/16 Primary

  Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)} · CPC title

• C07K14/001

  by chemical synthesis · CPC title